MetaCap

Ardelyx (ARDX) vs Syndax Pharmaceuticals (SNDX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ardelyx (ARDX) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, losing 44.8% versus a loss of 50.0%. Over five years, ARDX leads with a +234.8% price change compared with -47.1% for SNDX. Syndax Pharmaceuticals is the larger company by market cap ($785.0 million vs $751.6 million), about 1.0 times the size.

Ardelyx converts more of its revenue into profit, with a net margin of -15.1% versus -165.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARDX-44.83%SNDX-50.00%
+52%-2%-56%
Nov 21, 20251 yearNov 20, 2026
ARDX+199.00%SNDX-50.90%
+920%+412%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARDX versus SNDX key metrics
MetricARDXSNDX
Share price$2.99$8.72
Market cap$751.60M$785.05M
1-day change-2.29%-4.49%
YTD return-48.71%-58.50%
1-year return-44.83%-50.00%
5-year return+234.83%-47.09%
Forward P/E18.92—
EPS (TTM)$-0.23$-2.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$407.32M$172.35M
Revenue growth (YoY)+22.09%+627.84%
Net income (latest FY)$-61.60M$-285.42M
Gross margin90.29%—
Operating margin-10.06%-158.45%
Net margin-15.12%-165.60%
52-week high$8.40$25.59
52-week low$2.80$8.41
Distance from 52-week high-64.40%-65.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+318.06%+306.54%
Average volume4.46M2.63M
Shares outstanding251.37M90.03M
Employees489298
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Ardelyx is more profitable, keeping -15.1 cents of every revenue dollar as net income versus -165.6 cents for Syndax Pharmaceuticals.
  • Syndax Pharmaceuticals grew revenue faster in its latest fiscal year (+627.84% vs +22.09%).

About Ardelyx

ARDX stock →

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees

About Syndax Pharmaceuticals

SNDX stock →

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees

ARDX vs SNDX FAQ

Which is bigger, Ardelyx or Syndax Pharmaceuticals?

Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $785.05M compared with $751.60M for Ardelyx (ARDX).

Which stock has performed better over the past year, ARDX or SNDX?

ARDX returned -44.83% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.

Are Ardelyx and Syndax Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons